A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

NCT07541079 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Breast Cancer

Interventions

DRUG: Giredestrant

Sponsor

Genentech, Inc.